Mode
Text Size
Log in / Sign up

South Korea's July 2020 generic pricing policy increased marketed medicines by 1,811 unitsSouth Korea's New Drug Rules Sparked a Surge in Generic Options

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that South Korea's generic policy increased marketed medicines by 1,811 but requires monitoring for long-term sustainability.

This retrospective observational study assessed the impact of a new tiered pricing policy for generic medicines implemented in South Korea in July 2020. The policy linked reimbursement to bioequivalence testing and active pharmaceutical ingredient registration requirements. Data were analyzed from January 2017 through December 2022, comparing the post-policy period to the pre-policy period. The study population and sample size were not reported, and safety data such as adverse events or discontinuations were not reported.

Regarding primary outcomes, the number of marketed generic medicines showed a significant immediate increase of 1,811 units (p < 0.001). Following this initial surge, the trend in the number of generic medicines reversed from a pre-policy monthly increase to a post-policy decline, though specific effect sizes and p-values for this trend were not reported. The expenditure-based market share of generics did not show a significant immediate change. However, a significant positive trend in this market share was observed post-policy, increasing by +0.08 percentage points per month (p < 0.001).

Limitations of this study include the fact that the impact on product availability and generic uptake has not been fully evaluated. Funding sources and conflicts of interest were not reported. Given the observational nature of the design, causality cannot be definitively established. The practice relevance suggests that continued monitoring and class-specific complementary strategies are warranted to sustain long-term effectiveness.

South Korea's New Drug Rules Sparked a Surge in Generic Options

Imagine walking into a pharmacy and finding dozens of affordable copies of your prescription instead of just one expensive brand. That is exactly what happened in South Korea after a major policy change.

Before July 2020, the market for generic medicines was moving slowly. Patients often had to wait for specific brands to become available, which kept prices high. The frustration was real for families trying to save money on essential medications.

The Surprising Shift

In July 2020, South Korea changed the rules. They linked how much they would pay for a drug to two things: proving it works the same as the original and registering the main ingredient.

But here is the twist. Experts expected this to slow things down because of the extra testing. Instead, the opposite happened. The number of generic drugs on the market exploded almost overnight.

Think of the drug market like a crowded store. Before the new rules, only a few trusted brands were allowed on the shelves. The rest were locked out.

The new policy acted like a new door. It said, "If you prove your medicine is safe and effective, you can come in." Suddenly, many companies rushed to get their products approved. They had to show their drugs worked just like the famous brand versions.

This process ensures that every generic pill works the same way in your body. It stops companies from cutting corners on quality just to save money.

Researchers looked at data from January 2017 to December 2022. They used a special math method called interrupted time series analysis. This tool helps spot changes that happen right after a rule changes.

They studied thousands of different medicines across many health categories. The goal was simple: Did the new pricing rules actually change how many drugs were sold?

The results were clear and fast. Right after the policy started, the number of generic medicines jumped by 1,811 products. That is a massive increase in just a few months.

However, the story gets a little more complex. While the number of drugs went up, the total spending on generics did not change instantly. It took time for patients and doctors to switch to these new options.

Over the long term, the share of money spent on generics slowly grew. Every month after the policy, the percentage of spending on cheaper drugs went up by a small amount. This shows the change was real, even if it was gradual.

This doesn't mean this treatment is available yet.

That sentence is important to remember. This study was about a specific country and a specific time. It does not mean every patient can get these drugs today.

This news is good news for the future of affordable medicine. It shows that smart rules can force the market to work better for everyone.

If you are worried about high drug costs, this is a hopeful sign. Governments can use similar ideas to help lower prices without hurting quality.

The key takeaway is that quality checks do not have to mean higher prices. In fact, they can lead to more choices and better savings for families.

This policy in South Korea shows a clear path forward. Other countries might look at these results when they think about their own drug rules.

Researchers say we need to keep watching how this plays out. Will the number of generic drugs stay high? Will the savings last?

More studies will be needed to see if this model works in other places. The goal is to make sure everyone has access to safe, effective, and affordable medicine.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedMar 2026
View Original Abstract ↓
BackgroundSouth Korea introduced a new tiered pricing policy for generic medicines in July 2020, linking reimbursement to bioequivalence testing and active pharmaceutical ingredient registration requirements. While the policy aimed to improve market efficiency and quality assurance, its impact on product availability and generic uptake has not been fully evaluated.MethodsA retrospective observational study was conducted using the National Health Insurance Drug Master File and claims data from January 2017 to December 2022, with descriptive analyses covering 2017–2022. Interrupted time series (ITS) analysis with segmented regression was applied to assess changes in the number of marketed medicines and the expenditure-based market share of generics following the policy intervention, including stratified analyses by Anatomical Therapeutic Chemical level-1 categories. This study estimated policy effects using expenditure-based indicators under the revised reimbursement framework.ResultsThe policy resulted in a significant immediate increase in the number of generic medicines (+1,811; p < 0.001), followed by a reversal in trend from a pre-policy monthly increase to a post-policy decline. No significant immediate change was observed in the expenditure-based market share of generics; however, a significant positive post-policy trend was identified (+0.08 percentage points per month; p < 0.001).ConclusionSouth Korea’s tiered pricing policy led to rapid structural adjustments in the generic medicines market, with substantial short-term increases in product registrations and gradual increases in generic expenditure share over time. By linking pricing to quality-related requirements, the policy may strengthen market competitiveness and quality compliance. Continued monitoring and class-specific complementary strategies are warranted to sustain long-term effectiveness.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.